Quest Diagnostics Incorporated found using ticker (DGX) have now 15 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 185 and 150 and has a mean target at 165.33. Now with the previous closing price of 134.85 this indicates there is a potential upside of 22.6%. The 50 day MA is 155.19 while the 200 day moving average is 144.24. The company has a market cap of $16,564m. Find out more information at: https://www.questdiagnostics.com
The potential market cap would be $20,307m based on the market concensus.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
